Investigational drug · Phase 2
SYH2062
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mild to Moderate Primary Hypertension.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SYH2062"
First trial start
2026
Aug 11, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYH2062", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mild to Moderate Primary Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SYH2062" as an intervention, largest first.
- SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .Pivotal-lookingRecruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07940075 · 360 participants (planned) · Start Aug 11, 2026 · Primary completion Jan 31, 2027
Drug: SYH2062; Placebo · For: Mild to Moderate Primary Hypertension
Sites: Beijing, China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT06842537 · 46 participants (planned) · Start Mar 1, 2025 · Primary completion Dec 31, 2025
Drug: SYH2062 injection; SYH2062-Matching placebo · For: Healthy Chinese Volunteers
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.